Evidence map›Paper›PMID 26559180›Full record

Trial reportAIDS research and human retroviruses2016

Interferon-Free Treatment of Hepatitis C Virus in HIV/Hepatitis C Virus-Coinfected Subjects Results in Increased Serum Low-Density Lipoprotein Concentration.

Kerry Townsend, Eric G Meissner, Sreetha Sidharthan, Maureen Sampson, Alan T Remaley, Lydia Tang, Anita Kohli, Anu Osinusi, Henry Masur, Shyam Kottilil

Open access · greenAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in AIDS research and human retroviruses, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Observational
  10. Article
  11. Article
  12. Article
  13. The impact of direct-acting antiviral treatment on lipid metabolism and insulin resistance in chronic hepatitis C patients: temporary? permanent?The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2020
    Article
  14. Article
  15. Article
  16. Effect of sofosbuvir and daclatasvir on lipid profile, glycemic control and quality of life index in chronic hepatitis C, genotype 3 patients.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2019
    Observational
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Kerry Townsend1 Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, Maryland.
Eric G Meissner1 Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, Maryland.
Sreetha Sidharthan3 Critical Care Medicine Department, NIH Clinical Center , Bethesda, Maryland.
Maureen Sampson4 Clinical Center, Department of Laboratory Medicine, National Institutes of Health , Bethesda, Maryland.
Alan T Remaley5 Lipoprotein Metabolism Section, National Heart, Lung, and Blood Institute, National Institutes of Health , Bethesda, Maryland.
Lydia Tang6 Division of Infectious Diseases, Institute of Human Virology, University of Maryland , Baltimore, Maryland.
Anita Kohli3 Critical Care Medicine Department, NIH Clinical Center , Bethesda, Maryland.
Anu Osinusi2 Division of Infectious Diseases, Department of Microbiology and Immunology, Medical University of South Carolina , Charleston, South Carolina.
Henry Masur3 Critical Care Medicine Department, NIH Clinical Center , Bethesda, Maryland.
Shyam Kottilil1 Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, Maryland.
National Institutes of Health Clinical Center · USNational Institutes of Health · USGilead Sciences (United States) · USNational Institute of Allergy and Infectious Diseases · US

Funding

DC Partnership for HIV/AIDS Progress (DC PFAP)ZIACL009010 · CLC · CLINICAL CENTER · PI MASUR, HENRY · 2010 to 2025
$0k
Development Of New Assays For Lipoprotein TestingZIACL010303 · CLC · CLINICAL CENTER · PI REMALEY, ALAN THOMAS · 2009 to 2017
$0k
Intramural NIH HHS
6 · The paper itself

Abstract

Chronic hepatitis C virus (HCV) infection is associated with lower serum concentration of low-density lipoprotein (LDL-C), the primary cholesterol metabolite targeted pharmaceutically to modulate cardiovascular risk. Chronic infection with human immunodeficiency virus (HIV) and treatment with antiretrovirals (ARVs) are associated with dyslipidemia and increased risk of cardiovascular disease. In subjects coinfected with HIV and HCV, lipid abnormalities associated with either infection alone are often attenuated. Treatment of chronic HCV infection in HIV/HCV-coinfected subjects is now possible with interferon (IFN)-free regimens composed of directly acting antivirals (DAAs). We previously observed a marked increase in serum LDL-C in HCV-monoinfected subjects treated with sofosbuvir and ribavirin (SOF/RBV) that correlated with viral decline in serum, suggesting a direct influence of HCV clearance on serum cholesterol. In the present study, we assessed longitudinal changes in cholesterol in HIV/HCV-coinfected subjects during treatment of HCV genotype-1 (GT1) infection with combination DAA therapy. We report a rapid increase in LDL-C and LDL particle size by week 2 of treatment that was sustained during and after treatment in HIV/HCV-coinfected subjects. No change in serum LDL-C was observed at day 3 of treatment, in spite of a marked reduction in serum HCV viral load, suggesting LDL-C increases do not directly reflect HCV clearance as measured in peripheral blood. After effective DAA therapy for HCV, an increase in LDL should be anticipated in HIV/HCV-coinfected subjects.

Indexed as

Antiviral AgentsBenzimidazolesCardiovascular DiseasesCholesterol, LDLCoinfectionDrug Therapy, CombinationDyslipidemiasFemaleFluorenesFuransHepacivirusHepatitis C, ChronicHIV-1HIV InfectionsHumansMaleAntiviral AgentsBenzimidazolesCholesterol, LDLFluorenesFuransGS-9451GS-9669ledipasvirledipasvir, sofosbuvir drug combinationQuinolinesRibavirinSofosbuvirThiophenesUridine Monophosphate

Identifiers

PMID26559180
PMCPMC4845681
OpenAlexW2141725567

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.